NCT00828594View on ClinicalTrials.gov

Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

RAD001

DRUG

RAD001, sorafenib

Trial Locations (8)

27710

Duke University, Durham

90005

UCLA Department of Medicine, Los Angeles

91010

City of Hope Medical Center, Duarte

Unknown

Novartis Investigative Site, Amsterdam

Novartis Investigative Site, Seoul

Novartis Investigative Site, Barcelona

Novartis Invstigative Site, Madrid

Novartis Investigative Site, Tainan City

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY